Back to resultsBleb Vascularity Change After Subconjunctival Injection Bevacizumab
Primary Purpose
Bleb Vascularity, Conjunctival Scarring
Status
Unknown status
Phase
Phase 4
Locations
China
Study Type
Interventional
Intervention
bevacizumab
Sponsored by
About this trial
This is an interventional treatment trial for Bleb Vascularity focused on measuring bleb, vascular change, bevacizumab, trabeculectomy, Bleb vascularity associated with increased scarring activity, Conjunctival scarring finally leads to the obstruction of the fistula tract created by the filtering surgery, the recombinant human anti-VEGF antibody could inhibit angiogenesis of conjunctiva.
Eligibility Criteria
Inclusion Criteria:
- Glaucoma patients after trabeculectomy whose bleb is hyperaemia
Exclusion Criteria:
- Affected eye has normal IOP
- Not allergic with Avastin
Sites / Locations
- Tongren hospital
Outcomes
Primary Outcome Measures
bleb vascular change
Secondary Outcome Measures
Full Information
NCT ID
NCT00815594
First Posted
December 29, 2008
Last Updated
December 29, 2008
Sponsor
Capital Medical University
1. Study Identification
Unique Protocol Identification Number
NCT00815594
Brief Title
Bleb Vascularity Change After Subconjunctival Injection Bevacizumab
Official Title
Bleb Vascularity Change After Subconjunctival Injection of Bevacizumab
Study Type
Interventional
2. Study Status
Record Verification Date
December 2008
Overall Recruitment Status
Unknown status
Study Start Date
December 2008 (undefined)
Primary Completion Date
March 2009 (Anticipated)
Study Completion Date
May 2009 (Anticipated)
3. Sponsor/Collaborators
Name of the Sponsor
Capital Medical University
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The occurrence of conjunctival scarring finally leads to the obstruction of the fistula tract created by the filtering surgery. Vascular endothelial growth factor is thought to be a key role in the formation of conjunctival scar, which play a pivotal role in the wound-healing process. So it seems that the recombinant human anti-VEGF antibody could inhibit angiogenesis, and reduce the conjunctival vascular formation in the wound-healing process after glaucoma filtering surgery.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Bleb Vascularity, Conjunctival Scarring
Keywords
bleb, vascular change, bevacizumab, trabeculectomy, Bleb vascularity associated with increased scarring activity, Conjunctival scarring finally leads to the obstruction of the fistula tract created by the filtering surgery, the recombinant human anti-VEGF antibody could inhibit angiogenesis of conjunctiva.
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
30 (Anticipated)
8. Arms, Groups, and Interventions
Intervention Type
Drug
Intervention Name(s)
bevacizumab
Intervention Description
0.05ml, 1.25mg
Primary Outcome Measure Information:
Title
bleb vascular change
Time Frame
one day, one week, one month
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Glaucoma patients after trabeculectomy whose bleb is hyperaemia
Exclusion Criteria:
Affected eye has normal IOP
Not allergic with Avastin
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Liu Xuan, M.D.
Organizational Affiliation
An ophthalmologist in Tongren hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Tongren hospital
City
Beijing
State/Province
Beijing
ZIP/Postal Code
100730
Country
China
12. IPD Sharing Statement
Learn more about this trial
Bleb Vascularity Change After Subconjunctival Injection Bevacizumab
We'll reach out to this number within 24 hrs